Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

1. Guidance on Acute Management of Atrial Fibrillation in COVID?19 Full Text available with Trip Pro

Guidance on Acute Management of Atrial Fibrillation in COVID?19 Guidance on Acute Management of Atrial Fibrillation in COVID‐19 | Journal of the American Heart Association Search Search Hello Guest! Login to your account Email Password Keep me logged in Search Search June 2020 May 2020 April 2020 March 2020 February 2020 January 2020 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Open Access article Share on Jump to Open Access article Guidance (...) on Acute Management of Atrial Fibrillation in COVID‐19 , MD, , MD, , MD, , MD, , MD, , and MD, and MD1Division of Heart Rhythm Services Department of Cardiovascular Diseases Mayo Clinic Arizona Phoenix AZ Pattara Rattanawong Division of Heart Rhythm Services, , Department of Cardiovascular Diseases, , Mayo Clinic Arizona, , Phoenix, , AZ, , Win Shen Division of Heart Rhythm Services, , Department of Cardiovascular Diseases, , Mayo Clinic Arizona, , Phoenix, , AZ, , Hicham El Masry Division of Heart

2020 American Heart Association

2. Diagnostic accuracy of handheld electrocardiogram devices in detecting atrial fibrillation in adults in community versus hospital settings: a systematic review and meta-analysis

Diagnostic accuracy of handheld electrocardiogram devices in detecting atrial fibrillation in adults in community versus hospital settings: a systematic review and meta-analysis Diagnostic Accuracy of Handheld Electrocardiogram Devices in Detecting Atrial Fibrillation in Adults in Community Versus Hospital Settings: A Systematic Review and Meta-Analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search (...) Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Review Heart Actions . 2020 May 11;heartjnl-2020-316611. doi: 10.1136/heartjnl-2020-316611. Online ahead of print. Diagnostic Accuracy of Handheld Electrocardiogram Devices in Detecting Atrial Fibrillation in Adults in Community Versus Hospital Settings: A Systematic Review

2020 EvidenceUpdates

3. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS

Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Circulation Actions . 2020 May 19;141(20):1618-1627. doi: 10.1161/CIRCULATIONAHA.120.046534. Epub 2020 Mar 29. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome

2020 EvidenceUpdates

4. Meta-Analysis Comparing Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Atrial Fibrillation

Meta-Analysis Comparing Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Atrial Fibrillation Meta-Analysis Comparing Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Atrial Fibrillation - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library (...) displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Am J Cardiol Actions . 2020 Jul 1;126:23-28. doi: 10.1016/j.amjcard.2020.03.048. Epub 2020 Apr 8. Meta-Analysis Comparing Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Atrial Fibrillation , , , Affiliations Expand Affiliations 1 Department of Clinical Pharmacy, West Virginia University School of Pharmacy, Morgantown, West Virginia. Electronic address: kazuhiko.kido0322@gmail.com. 2

2020 EvidenceUpdates

5. HRS White Paper on Atrial Fibrillation Centers of Excellence: Rationale, Considerations, and Goals

HRS White Paper on Atrial Fibrillation Centers of Excellence: Rationale, Considerations, and Goals Journal Pre-proof HRS white paper on atrial fibrillation centers of excellence: Rationale, considerations, and goals Jonathan P. Piccini, Sr., MD, MHS, FHRS (Chair), James Allred, MD, FHRS, T. Jared Bunch, MD, FHRS, Thomas F. Deering, MBA, MD, FHRS, CCDS, Luigi Di Biase, MD, PhD, FHRS, Ayman A. Hussein, MD, FHRS, William R. Lewis, MD, FHRS, Suneet Mittal, MD, FHRS, Andrea Natale, MD, FHRS, Jose (...) .2020.04.033 Reference: HRTHM 8371 To appear in: Heart Rhythm Received Date: 27 April 2020 Accepted Date: 27 April 2020 Please cite this article as: Piccini Sr JP, Allred J, Bunch TJ, Deering TF, Di Biase L, Hussein AA, Lewis WR, Mittal S, Natale A, Osorio J, Packer DL, Ruff C, Russo AM, Sanders P, Seiler A, Slotwiner D, Hills MT, Turakhia MP, Van Gelder IC, Varosy PD, Verma A, Volgman AS, Wood KA, Deneke T, HRS white paper on atrial fibrillation centers of excellence: Rationale, considerations, and goals

2020 Heart Rhythm Society

6. Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation. (Abstract)

Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation. It is unclear whether anticoagulant type is associated with the risk for osteoporotic fracture, a deleterious complication of anticoagulants among patients with atrial fibrillation (AF).To compare the risk for osteoporotic fracture between anticoagulants.Population-based cohort study.Territory-wide electronic health record database

2020 Annals of Internal Medicine

7. Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation

Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center for Biotechnology Information Show account info (...) : 10.1016/j.jacc.2020.01.052. Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation , , , , , , , , , , , , , , , , , , , , , , Collaborators, Affiliations Expand Collaborators mAF-App II Trial Investigators : , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations 1 Medical School of Chinese PLA, Department of Cardiology, Chinese PLA General Hospital, Beijing, China. 2 Liverpool

2020 EvidenceUpdates

8. Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (from the National Cardiovascular Disease Registry`s Practice Innovation and Clinical Excellence Registry)

Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (from the National Cardiovascular Disease Registry`s Practice Innovation and Clinical Excellence Registry) Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (From the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence Registry) - PubMed This site needs JavaScript to work properly. Please enable (...) when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Am J Cardiol Actions . 2020 May 15;125(10):1500-1507. doi: 10.1016/j.amjcard.2020.02.028. Epub 2020 Mar 5. Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (From the National Cardiovascular Disease Registry's Practice Innovation and Clinical

2020 EvidenceUpdates

9. Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice: A Cohort Study. (Abstract)

Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice: A Cohort Study. Apixaban and rivaroxaban are the most commonly prescribed direct oral anticoagulants for adults with atrial fibrillation, but head-to-head data comparing their safety and effectiveness are lacking.To compare the safety and effectiveness of apixaban versus rivaroxaban for patients with nonvalvular atrial fibrillation.New-user, active-comparator, retrospective (...) of gastrointestinal bleeding or intracranial hemorrhage (12.9 per 1000 person-years) compared with those prescribed rivaroxaban (21.9 per 1000 person-years), corresponding to an HR of 0.58 (CI, 0.52 to 0.66) and a rate difference of 9.0 fewer events per 1000 person-years (CI, 6.9 to 11.1).Unmeasured confounding, incomplete laboratory data.In routine care, adults with atrial fibrillation prescribed apixaban had a lower rate of both ischemic stroke or systemic embolism and bleeding compared with those prescribed

2020 Annals of Internal Medicine

10. Does mitral annuloplasty fall under the definition of “valvular atrial fibrillation”?

Does mitral annuloplasty fall under the definition of “valvular atrial fibrillation”? Chiefs’ Inquiry Corner – 3/16/20 – Clinical Correlations Search Chiefs’ Inquiry Corner – 3/16/20 March 16, 2020 2 min read Conventionally, anticoagulation with warfarin has been the prefered method of stroke prevention in patients with valvular atrial fibrillation. In January 2019, the AHA/ACC/HRS Guidelines on the Management of Atrial Fibrillation clarified the definition of valvular a fib, restricting

2020 Clinical Correlations

11. Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association | Circulation Search Search Hello Guest! Login to your account Email Password Keep me logged in Search Search April 2020 March 2020 February 2020 January 2020 This site uses cookies. By continuing to browse this site you (...) are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association , MD, FAHA, Chair , MD, Co–Vice Chair , MD, MS, FAHA, Co–Vice Chair , MD, MPH, FAHA , MD, MA, FAHA , MD, FAHA , MD , MD, MSc, FAHA , MBBS, PhD, FAHA , MD Mina K. Chung , Lee L. Eckhardt , Lin Y. Chen , Haitham M. Ahmed , Rakesh Gopinathannair , José A. Joglar , Peter A. Noseworthy

2020 American Heart Association

12. Relation of Frailty to Outcomes After Catheter Ablation of Atrial Fibrillation

Relation of Frailty to Outcomes After Catheter Ablation of Atrial Fibrillation Relation of Frailty to Outcomes After Catheter Ablation of Atrial Fibrillation - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health U.S. National Library of Medicine National (...) . 2020 May 1;125(9):1317-1323. doi: 10.1016/j.amjcard.2020.01.049. Epub 2020 Feb 8. Relation of Frailty to Outcomes After Catheter Ablation of Atrial Fibrillation , , , , , , Affiliations Expand Affiliations 1 Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. 2 Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester

2020 EvidenceUpdates

13. What is the appropriate initial workup for a patient with newly diagnosed atrial fibrillation?

What is the appropriate initial workup for a patient with newly diagnosed atrial fibrillation? Chiefs’ Inquiry Corner – 3/2/20 – Clinical Correlations Search Chiefs’ Inquiry Corner – 3/2/20 March 2, 2020 2 min read Beyond considerations for rate or rhythm control and anticoagulation, it is recommended that all patients newly diagnosed with atrial fibrillation undergo a basic workup to determine any underlying etiologic causes. This includes a thorough history and physical exam. Additionally

2020 Clinical Correlations

14. External Performance of the HAVOC Score for the Prediction of New Incident Atrial Fibrillation (Abstract)

External Performance of the HAVOC Score for the Prediction of New Incident Atrial Fibrillation Background and Purpose- The HAVOC score (hypertension, age, valvular heart disease, peripheral vascular disease, obesity, congestive heart failure, coronary artery disease) was proposed for the prediction of atrial fibrillation (AF) after cryptogenic stroke. It showed good model discrimination (area under the curve, 0.77). Only 2.5% of patients with a low-risk HAVOC score (ie, 0-4) were diagnosed

2020 EvidenceUpdates

15. Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis (Abstract)

Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis Patients on long-term dialysis are at increased risk of bleeding. Although oral anticoagulants (OACs) are recommended for atrial fibrillation (AF) to reduce the risk of stroke, randomized trials have excluded these populations. As such, the net clinical benefit of OACs among patients on dialysis is unknown.This study aimed to investigate the efficacy and safety of OACs in patients with AF on long-term

2020 EvidenceUpdates

16. Comparison of the Effect of Age (< 75 Versus >/= 75) on the Efficacy and Safety of Dual Therapy (Dabigatran+Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin+Aspirin+Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneo Full Text available with Trip Pro

Comparison of the Effect of Age (< 75 Versus >/= 75) on the Efficacy and Safety of Dual Therapy (Dabigatran+Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin+Aspirin+Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneo Comparison of the Effect of Age ( - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History (...) in the 2 age groups, which may help dose selection when using dabigatran dual therapy. Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved. Similar articles CP Cannon et al. N Engl J Med 377 (16), 1513-1524. 2017. PMID 28844193. - Randomized Controlled Trial Among patients with atrial fibrillation who had undergone PCI, the risk of bleeding was lower among those who received dual therapy with dabigatran and a P2Y 12 … M Maeng et al. JACC Cardiovasc Interv 12 (23), 2346-2355

2020 EvidenceUpdates

17. Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study Full Text available with Trip Pro

Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study Vitamin K antagonists (VKAs), although commonly used to reduce thromboembolic risk in atrial fibrillation, have been incriminated as probable cause of accelerated vascular calcification (VC) in patients on hemodialysis. Functional vitamin K deficiency may further contribute to their susceptibility for VC. We (...) investigated the effect of vitamin K status on VC progression in 132 patients on hemodialysis with atrial fibrillation treated with VKAs or qualifying for anticoagulation.Patients were randomized to VKAs with target INR 2-3, rivaroxaban 10 mg daily, or rivaroxaban 10 mg daily plus vitamin K2 2000 µg thrice weekly during 18 months. Systemic dp-ucMGP levels were quantified to assess vascular vitamin K status. Cardiac and thoracic aorta calcium scores and pulse wave velocity were measured to evaluate VC

2020 EvidenceUpdates

18. Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial. (Abstract)

Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial. Acute atrial fibrillation is the most common arrythmia treated in the emergency department. Our primary aim was to compare conversion to sinus rhythm between pharmacological cardioversion followed by electrical cardioversion (drug-shock), and electrical cardioversion alone (shock-only). Our secondary aim was to compare the effectiveness (...) of two pad positions for electrical cardioversion.We did a partial factorial trial of two protocols for patients with acute atrial fibrillation at 11 academic hospital emergency departments in Canada. We enrolled adult patients with acute atrial fibrillation. Protocol 1 was a randomised, blinded, placebo-controlled comparison of attempted pharmacological cardioversion with intravenous procainamide (15 mg/kg over 30 min) followed by electrical cardioversion if necessary (up to three shocks, each

2020 Lancet

19. Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial. (Abstract)

Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial. Renal denervation can reduce cardiac sympathetic activity that may result in an antiarrhythmic effect on atrial fibrillation.To determine whether renal denervation when added to pulmonary vein isolation enhances long-term antiarrhythmic efficacy.The Evaluate Renal (...) Denervation in Addition to Catheter Ablation to Eliminate Atrial Fibrillation (ERADICATE-AF) trial was an investigator-initiated, multicenter, single-blind, randomized clinical trial conducted at 5 referral centers for catheter ablation of atrial fibrillation in the Russian Federation, Poland, and Germany. A total of 302 patients with hypertension despite taking at least 1 antihypertensive medication, paroxysmal atrial fibrillation, and plans for ablation were enrolled from April 2013 to March 2018

2020 JAMA

20. Alcohol Abstinence in Drinkers with Atrial Fibrillation. (Abstract)

Alcohol Abstinence in Drinkers with Atrial Fibrillation. Excessive alcohol consumption is associated with incident atrial fibrillation and adverse atrial remodeling; however, the effect of abstinence from alcohol on secondary prevention of atrial fibrillation is unclear.We conducted a multicenter, prospective, open-label, randomized, controlled trial at six hospitals in Australia. Adults who consumed 10 or more standard drinks (with 1 standard drink containing approximately 12 g of pure alcohol (...) ) per week and who had paroxysmal or persistent atrial fibrillation in sinus rhythm at baseline were randomly assigned in a 1:1 ratio to either abstain from alcohol or continue their usual alcohol consumption. The two primary end points were freedom from recurrence of atrial fibrillation (after a 2-week "blanking period") and total atrial fibrillation burden (proportion of time in atrial fibrillation) during 6 months of follow-up.Of 140 patients who underwent randomization (85% men; mean [±SD] age

2020 NEJM